National Survey of Drug-Resistant Tuberculosis in China Dr. Yanlin Zhao
|
|
- Ophelia Douglas
- 5 years ago
- Views:
Transcription
1 National Survey of Drug-Resistant Tuberculosis in China Dr. Yanlin Zhao National Centre for Tuberculosis Control and Prevention of China CDC National TB Reference Laboratory, China CDC
2 BACKGROUND China lists as 2 nd among the 22 TB high-burden countries. In 1979, 1984/1985, 1990, 2000, nationwide epidemiological prevalence survey. Prevalence survey in 2000 shows 18.6% of initial resistance and 46.5% acquired resistance. During 1996~2008, 13 province have taken part in drugresistance surveillance organized by WHO/IUATLD. Initial: 14.8%~42.1%; Acquired: 33.7%~66% Estimation of MDR-TB in China: 5.0%, 26%
3 Objectives 1. To interpret the epidemiological status of drug resistant tuberculosis in China 2. To analyze the risk factor for drug resistance occurrence among tuberculosis patients 3. To explore the predominant mycobacterium bacillus biological characteristics in China 4. To understand the micro-evolution of the prevalent strains in China.
4 Selection of the 70 sites 70 clusters (sites) were selected according to new smear-positive cases reported by each province relative to the total number of cases nationwide in 2004 and All provinces should have at least one cluster.
5 Method 1.70 clusters(counties) from all 31 provinces 2.51 smear positive new cases and 17 smear positive retreatment cases with newly diagnosed 3. DST(proportion method) against 6 anti-tb drugs 1/29/2013 5
6 Design and preparation 2 Pilots
7 Design and Preparation Experience and lessons
8 Design and preparation Training objectives: all persons(about 700 persons) involved in this survey Training contents: Interaction method, role play and practice
9
10 Resource of reagents and disposables for the laboratory
11 Anti-TB baseline survey lauching meeting ( 1 st Apr. 2007) Record files and register book
12 Logistics Monthly report Newsletter special address special fixed telephone fixed people 24h response established reporting and recording feedback machanism
13 Quality assurrance Leader group Experts panel Executive office Standardization of definition Standardization of methods Standardization of the parameters of the equipment, reagents and disposals Standardization of the implementation period of the time
14 Supervision Supervision for all clusters, Special supports to priority sites( 2 people from central level work in Tibet 3 weeks)
15 Strain files management
16 Strain logistic box special vehicle
17 Consent informs Questionaires
18 Panel testing for all persons who are responsible for DST Panel testing from Hongkong Supernational Reference Laboratory
19 Database of investigation Data input double blinded input the data by Peking University and 100% recheck by NRL
20 DST work in NRL Lowenstein-Jensen (L-J) media and proportion method was used for DST. 6 anti-tb drugs were included: sonazied(inh), Rifampine(RFP), Streptomycin(SM), Ethembutol(EMB), ofloxacin (Ofx); Kanamycin(Km) Proficiency test for DST was done to NRL by Hong Kong Super-National reference laboratory. 10% of the isolates were randomly chosen to repeat DST, the outcome was eligible according to WHO s guideline. Species identification work in NRL Selective L-J media method was used.
21 Case Enrollment & Culture Result Category Anticipated # Actual Completeness Estimated Culture + New Patient % 3010 TB 3037 NTM 103 Treated Patient % 1010 TB 892 NTM 37 Total # : considering 15% loss of samples due to failure to recover the culture or to growth of NTM. New patiens: 3010/ ; Treated patients: 1010/ : calculated under the estimation that drug resistance rate in new cases is 6% and 16% in previously treated cases, with a precision of ±1.2% / ±3.2% for CI 95% and a design effect of 2.
22 Results TB tested from 4069 cases Percentage of MDR-TB New case 5.71% Retreated case 25.64% Total 8.32% Percentage of XDR-TB New case 0.47% Retreated case 2.06% Total 0.68% thousand annually and 9 thousand cases among them are XDR patients. 1/29/
23 National prevalence of drug-resistant TB: China (2007) New cases (N = 3037) Previously treated cases (N =892) n (%) 95% CI n (%) 95% CI Susceptible to all 4 first line drugs 2009 (65.8) (45.5) Resistance to INH or RMP (not both) 338 (11.2) (16.1) Multidrug resistance (MDR) 175 (5.7) (25.6) Any resistance to OFX or KM 131 (4.2) (11.4) OFX resistance 88 (2.7) (8.7) KM resistance 59 (2.0) (4.8) MDR + resistance to OFX or KM 58 (1.8) (8.5) Extensively drug resistance 15 (0.47) (2.1) Zhao et al, NEJM, 2012
24 Previously treated MDRTB cases: last treatment completion and the location of last treatment Zhao et al, NEJM, 2012 January 29, Bill & Melinda Gates Foundation 24
25 Risk factors for drug-resistant TB among previously treated cases Drug-resistant TB (non-mdr)* Multidrug- resistant TB Women 1.7 ( ) 2.2 ( ) Age >60 years 0.79 ( ) 0.42 ( ) Lived in area with DOTS implementation after ( ) 1.7 ( ) No. of prior TB treatment episodes and medical facility providing last TB treatment One prior treatment and other medical facilities 1.0 (Ref) 1.0 (Ref) One prior treatment and TB hospital 1.6 ( ) 1.5 ( ) 2 prior treatments and other medical facilities 1.5 ( ) 3.3 ( ) 2 prior treatments and TB hospital 4.0 (1.2-14) 13 (3.9-46) Zhao et al, NEJM, 2012 January 29, Bill & Melinda Gates Foundation 25
26 Preventing MDRTB: new tools + system change Reduce sub-optimal treatment in CDC and hospital system by using treatment regimens based on resistance testing Make sure patients starting treatment in hospitals are followed up after discharge till they complete treatment; build linkage between hospital system and CDC system Improve treatment provided by TB hospitals: appropriate drug regimens, improved infection control, better follow-up after discharge Improve community case-management of patients on treatment (perhaps using adherence technology) January 29, Bill & Melinda Gates Foundation 26
27 Building hospital-cdc collaboration to prevent and treat M/XDR TB CDC system Patients evaluated for TB Specialized hospital Patients evaluated for TB No MDR MDR No MDR M/XDR Routine treatment (1 st -line drugs) M/XDR treatment (2 nd -line drugs) Effective case management in community
28 DOTS Program (in CDC) Diagnosis Smear microscopy Empiric treatment Standardized regimen using 1 st -line drugs Community casemanagement Self or family members Hospital-CDC collaboration Financing model for MDRTB Quality-assured drugs Incentive model for HCW s Innovative Program (CDC & hospital) Molecular diagnosis Rapid dx of TB Rapid dx of MDR-TB Treatment based on testing for resistance 2 nd -line drugs for MDR 1 st -line FDC drugs for non-mdr Technology-supported case-management Use of mobile phone & med monitor
29 Risk factors for drug-resistant TB among new cases Drug-resistant TB (non-mdr)* Multidrug- resistant TB Women 0.90 ( ) 1.5 ( ) Age >60 years 0.88 ( ) Occupation as non-farmer 1.2 ( ) 1.4 ( ) Lived in area with DOTS implementation after ( ) History of treatment with TB drugs and prior TB diagnosis No treatment (with or without a prior TB diagnosis) 1.0 (Ref) 1.0 (Ref) Treatment of <1 month and a prior TB diagnosis 1.6 ( ) 1.2 ( ) Treatment of any duration and no prior TB diagnosis 1.2 ( ) 2.4 ( ) Zhao et al, NEJM, 2012 January 29, Bill & Melinda Gates Foundation 29
30 Preventing drug-resistant TB among new cases Who are the patients with no prior diagnosis of TB but given TB drugs? Likely suspected to have TB and started on TB drugs Did not receive a diagnosis of TB because proper diagnosis not made Took TB drugs long enough, but improperly, such that MDRTB developed Mostly treated in hospital system Importance of performing proper diagnosis January 29, 2013 of TB 2011 Bill & Melinda Gates Foundation 30
31 Implications for new drug R&D Important to turn off the tap of DR-TB Current factors causing DR-TB will lead to rapid loss of any new drug to resistance Urgency in light of new TB drugs becoming available TMC-207, OPC67683, linozelid Need to improve system, adopt new diagnostics, and use new drugs in a rational manner in order to prevent DR-TB Level of quinolone resistance has 2011 Bill & Melinda Gates January 29, 2013 Foundation 31
32 Questions continues What s the population structure of the prevalent TB strains in China? What advantages do they have to become the prevalent strains? How do the prevalent strains interact with hosts and environment?
33 Drug resistance pattern 4000 TB Strains Drug resistant related mutations Spoligotyping 24 loci MIRU-VNTR plus IS6110 RFLP BJ/non-BJ strains Virulence & Pathogenicity Whole Genome Sequencing SNPs
34
35 Distribution map of different spoligotypes
36
37
38 Phenotypic drug resistance profiles and epidemiologic data of 11 Chinese M. tuberculosis isolates Isolates Virulence First-line drug resistance a Second-line drug resistance b Type Gender Age, years Genotype INH, RIF MDR Male 86 Beijing EMB Susceptible Male 17 Beijing INH, STR, EMB, RIF MDR Female 16 Beijing INH, STR, EMB, RIF MDR Female 16 Beijing INH, STR Susceptible Female 75 Beijing INH, STR Susceptible Male 34 Beijing STR OFX Susceptible Male 63 Beijing Susceptible Male 77 Beijing STR Susceptible Male 61 Non-beijing INH, RIF MDR Female 59 Non-beijing INH Susceptible Female 18 Non-beijing INH Susceptible Male 69 Non-beijing H37Rv 12 Susceptible Non-beijing
39 Table 2. Shared mutations in the high virulent strains Locus Id Nn-synonymous Mtation Fund Anotation a b c d e f Rv0336 Y376C Y376C Y376C 13E12 repeat family protein Rv0515 Y376C Y376C Y376C 13E12 repeat family protein Rv0775 R86Q R86Q R86Q R86Q hypothetical protein Rv0775 Rv1152 G105A G105A G105A G105A transcriptional regulatory protein Rv1295 G237S G237S G237S G237S threonine synthase Rv1588c A63T A63T A63T A63T REP13E12 repeat-containing protein Rv1934c N102S N102S N102S N102S acyl-coa dehydrogenase FADE17 Rv2124c Y1098D Y1098D Y1098D Y1098D 5-methyltetrahydrofolate-- homocystein methyltransferase Rv2769c A136V A136V A136V A136V PE family protein Rv3774 G124D G124D G124D G124D enoyl-coa hydratase Rv2543 A138V,A 139T A138V,A 139T A138V,A 139T A138V,A 139T A138V,A 139T A138V,A 139T lipoprotein LppA
40 Position of the 871 nonsynonymous SNPs by excluding common SNPs in Beijing genotype and non- Beijing genotype, respectively, Positions are Relative to the M. tuberculosis H37Rv Genome Sequence (From inner to outer: , , , , , , , , , , , green indicates susceptible strains, cyan indicates MDR strains)
41 Visible TB distribution model
42 大气监测数据可视化
43 4 dimension distribution by Genotypes
44 分枝杆菌迁徙可视化效果图
45 Acknowledgement people who made efforts and contribution to the survey Disease Prevention and Control Center of China (CDC) Beijing Tuberculosis and Thoracic Tumor Institute Peking Union Medical College of China Beijing University of China 31 provincial TB dispensary and 70 clusters
46
47 Thank you for your attention!
Qian Gao Fudan University
Qian Gao Fudan University Outline Background & Objectives Genotyping methods Establish the epidemiological field sites Preliminary results of Molecular epidemiology of TB in China Molecular epidemiology
More informationMDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT
TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words
More informationTransmission of MDR/XDR Tuberculosis in Shanghai. Qian Gao Shanghai Medical College Fudan University
Transmission of MDR/XDR Tuberculosis in Shanghai Qian Gao Shanghai Medical College Fudan University Drug Resistant TB in China The Highest DR-TB Burden Country New TB cases/year Cases with any DR MDR XDR
More informationXpert MTB/RIF assay validation experience --- impact and plan in China
Xpert MTB/RIF assay validation experience --- impact and plan in China Dr. Zhao Yanlin Chinese Center for Disease Control & Prevention Dr. Richard O Brien FIND April. 16, 2013 Progress Contribution for
More informationTransmissibility, virulence and fitness of resistant strains of M. tuberculosis. CHIANG Chen-Yuan MD, MPH, DrPhilos
Transmissibility, virulence and fitness of resistant strains of M. tuberculosis CHIANG Chen-Yuan MD, MPH, DrPhilos Transmissibility, Virulence and Fitness of resistant strains of M. tuberculosis For infectious
More informationPrevalence of resistance to second-line tuberculosis drug among multidrugresistant tuberculosis patients in Viet Nam, 2011
Original Research Prevalence of resistance to second-line tuberculosis drug among multidrugresistant tuberculosis patients in Viet Nam, 2011 Hoa Binh Nguyen, ab Nhung Viet Nguyen, ac Huong Thi Giang Tran,
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationTB trends and TB genotyping
Management of a TB Contact Investigation for Public Health Workers Albuquerque, NM October 1, 214 TB trends and TB genotyping Marcos Burgos MD October 1, 214 Marcos Burgos, MD has the following disclosures
More informationHow best to structure a laboratory network with new technologies
How best to structure a laboratory network with new technologies Cristina Gutierrez, MD, PhD Uniting to scale up TB care in Central Asia 14 and 15 April 2011 Tashkent, Uzbekistan New laboratory diagnostics
More informationOnline Annexes (2-4)
Online Annexes (2-4) to WHO Policy update: The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin THE END TB STRATEGY Online Annexes (2-4) to WHO Policy update:
More informationTB Control in Finland - the role of THL
TB Control in Finland - the role of THL Hanna Soini THL, Department of Health Security 1 TB in Finland 1950-2014 12000 10000 8000 6000 TB ulkomaalaiset TB yhteensä 4000 2000 0 1950 1955 1960 1965 1970
More informationMolecular Epidemiology of Tuberculosis. Kathy DeRiemer, PhD, MPH School of Medicine University of California, Davis
Molecular Epidemiology of Tuberculosis Kathy DeRiemer, PhD, MPH School of Medicine University of California, Davis Overview TB transmission and pathogenesis Genotyping methods Genotyping for clinical management
More informationMULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic
MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin
More informationDiagnostic and treatment delays of multidrug-resistant tuberculosis before initiating treatment: a cross-sectional study
Tropical Medicine and International Health doi:10.1111/tmi.12566 volume 20 no 11 pp 1431 1437 november 2015 Diagnostic and treatment delays of multidrug-resistant tuberculosis before initiating treatment:
More informationDrug resistance surveillance: progress to date and emerging innovations
Drug resistance surveillance: progress to date and emerging innovations Anna Dean Matteo Zignol WHO Global Task Force on TB Impact Measurement Glion-sur-Montreux 19 21 April 2016 1. Global project on anti-tb
More informationThe WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps
The WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps Matteo Zignol STOP TB Department World Health Organization TB surveillance and
More informationKristina Wallengren, PhD MPH
Kristina Wallengren, PhD MPH Head of Clinical Research K-RITH South Africa K-RITH S AIM: TO CONDUCT EXCELLENT BASIC SCIENCE IN TB AND HIV XDR TB outbreak in Tugela Ferry, KwaZulu-Natal, 2005 XDR TB PREVALENCE
More informationLaboratory s Role in the Battle Against Drug Resistant Tuberculosis
Laboratory s Role in the Battle Against Drug Resistant Tuberculosis Angela M. Starks, Ph.D. Chief, Laboratory Branch Division of Tuberculosis Elimination June 6, 2016 National Center for HIV/AIDS, Viral
More informationDiagnosis of drug resistant TB
Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million
More informationApplication of the Onion model to assess the extent of missing tuberculosis cases by the National Programmes
Application of the Onion model to assess the extent of missing tuberculosis cases by the National Programmes Dr Amal Bassili Stop TB unit, WHO, Regional Office for the Eastern Mediterranean Surveillance
More informationNext Generation TB Diagnostics An Update from BMGF. Lee Pyne-Mercier
Next Generation TB Diagnostics An Update from BMGF Lee Pyne-Mercier November 2012 Presentation Outline Foundation Strategic Context Next Generation TB Diagnostics Program TB Diagnostics Forum November
More informationScott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer
Tuberculosis in the 21 st Century Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer Feedback Poll In my opinion, the recent media coverage of
More informationWHERE DO WE GO FROM HERE?
WHERE DO WE GO FROM HERE? WHAT WILL BE REQUIRED TO ACHIEVE ZERO DEATHS FROM TUBERCULOSIS? SALMAAN KESHAVJEE, MD, PHD, SCM HARVARD MEDICAL SCHOOL BRIGHAM AND WOMEN S HOSPITAL PARTNERS IN HEALTH INTERNATIONAL
More informationMolecular Epidemiology and Clinical Characteristics of Drug-Resistant Mycobacterium tuberculosis in a Tuberculosis Referral Hospital in China
Molecular Epidemiology and Clinical Characteristics of Drug-Resistant Mycobacterium tuberculosis in a Tuberculosis Referral Hospital in China Qi Wang 1., Susanna K. P. Lau 2., Fei Liu 1., Yanlin Zhao 3,
More informationAssessing the programmatic management of drug-resistant TB
Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many
More informationTitle: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis.
Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Principal Investigator: Dick Menzies, MD Evidence base for treatment of INH resistant
More informationMolecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA
SURVEILLANCE REPORT Molecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA March 2017 Summary This report describes the geographical and temporal distribution of multidrug-resistant
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Churchyard GJ, Stevens WS, Mametja LD, et al.
More informationOnline Annexes (5-8)
2016 Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs 1 Contents: Annex 5: GRADE summary of findings
More informationShort Course Treatment for MDR TB
Objectives Short Course Treatment for MDR TB Barbara J Seaworth M.D. Medical Director Heartland National TB Center Professor of Medicine, University of Texas Health Northeast Participants will utilize
More informationInternational Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007
TB Along the US/Mexico Border El Paso, Texas August 22-23, 2007 International Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007 Barbara J Seaworth MD Medical Director Heartland National
More informationHow Is TB Transmitted? Sébastien Gagneux, PhD 20 th March, 2008
How Is TB Transmitted? Sébastien Gagneux, PhD 20 th March, 2008 Today s Outline 1) Global spread of Mtb Comparative genomics Phylogeny 2) Transmission of drug-resistant Mtb Fitness assays Molecular epidemiology
More informationA ten-year evolution of a multidrugresistant tuberculosis (MDR-TB) outbreak in an HIV-negative context, Tunisia ( )
A ten-year evolution of a multidrugresistant tuberculosis (MDR-TB) outbreak in an HIV-negative context, Tunisia (2001-2011) Naira Dekhil 1, Besma Mhenni 1, Raja Haltiti 2, and Helmi Mardassi 1 (speaker)
More informationGlobal Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics
Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics Neel R. Gandhi, MD Emory Rollins School of Public Health January 17, 2013 Medical Research Council BMJ 1948
More informationOnline Annexes (5-8)
Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs THE END TB STRATEGY Online Annexes (5-8) to WHO
More informationMultidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017
Multidrug-/ rifampicinresistant TB (MDR/RR-TB): Update 2017 The global TB situation (1) Estimated incidence, 2016 Estimated number of deaths, 2016 All forms of TB HIV-associated TB Multidrug- / rifampicin-resistant
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationRam Sharan Gopali (MPH) Executive Director
Ram Sharan Gopali (MPH) Executive Director Basic Facts of Nepal Nepal is a landlocked country located in the WHO Asian region at the edge of the Himalaya between India and the Peoples Republic of China
More informationDiagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014
TB Nurse Case Management San Antonio, Texas April 1 3, 2014 Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant
More informationTB infection control: overview and importance
TB infection control: overview and importance John Ferguson, Newcastle, NSW Infectious Diseases & Microbiology jferguson@hnehealth.nsw.gov.au Goroka Hospital, September 2014 Patterns of TB disease Latent
More informationMolecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA
Molecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA January 2016 Summary This report describes the geographical and temporal distribution of multidrug-resistant (MDR) tuberculosis
More informationDrug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye
Director of Health Information World Health Organization Geneva 1 1. Why TB patients are treated with drugs 2 Natural history and control of TB Fast 5/1 Slow 5/1 Uninfected Latent Active 1 1 infection/case
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationStudy of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan
Journal of Basic & Applied Sciences, 2018, 14, 107-112 107 Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan Sana Saeed 1, Moosa Raza
More informationTB 101 Disease, Clinical Assessment and Lab Testing
TB 101 Disease, Clinical Assessment and Lab Testing Pacific Islands Tuberculosis Controllers Association Conference (PITCA) Clinical Laboratory Breakout None Disclosure Objectives Be able to list and explain
More informationPrinciple of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos
Principle of Tuberculosis Control CHIANG Chen-Yuan MD, MPH, DrPhilos Estimated global tuberculosis burden 2015 an estimated 10.4 million incident cases of TB (range, 8.7 million 12.2 million) 142 cases
More informationMolecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis.
Title Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium. Author(s) Ho, PL; Yam, WC; Leung, CC; Yew, WW; Mok, TYW; Chan, KS; Tam, CM Citation Hong Kong Medical
More informationEpidemiology and diagnosis of MDR-TB in children H Simon Schaaf
Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Definitions
More informationRevised National Tuberculosis Control Programme
Revised National Tuberculosis Control Programme 1 OUTLINE OF PRESENTATION Introduction Burden Of The Disease Evolution Of RNTCP Goals And Objectives Of RNTCP DOTS Stop TB Strategy Organization RNTCP Endorsed
More informationOUT-TB Web. Ontario Universal Typing of Tuberculosis: Surveillance and Communication System
OUT-TB Web Ontario Universal Typing of Tuberculosis: Surveillance and Communication System Dr. Frances Jamieson, Ontario Public Health Laboratories November 30 th, 2009 Tuberculosis : A Global Problem
More informationNational Survey of Drug-Resistant Tuberculosis in China
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article National Survey of Drug-Resistant Tuberculosis in China Yanlin Zhao, Ph.D., Shaofa Xu, M.D., Lixia Wang, M.S., Daniel P. Chin, M.D.,
More information7. Are you currently engaged in research that could support new TB diagnostic assay development? Yes No
Determining Future TB Reference Material Requirements WHO/TDR TB Expert & End-User Survey Properly handled samples from well-characterized patients with suspected tuberculosis from disease endemic countries
More informationDefinitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013
Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 2-year revision process WHO/HTM/TB/2013.2 2 www.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
More informationNational TB Prevalence survey in Myanmar. By Dr. Thandar Lwin Programme Manager National TB Programme Department of Health
National TB Prevalence survey in Myanmar By Dr. Thandar Lwin Programme Manager National TB Programme Department of Health 58 million pop. 676,577 sq km (75/sq km) S+ notification rate/100,000 population
More informationAPSR RESPIRATORY UPDATES
APSR RESPIRATORY UPDATES Volume 5, Issue 2 Newsletter Date: February 2013 APSR EDUCATION PUBLICATION Inside this issue: Tuberculosis Multidrug-resistant pulmonary tuberculosis treatment regimens and patient
More informationXDR and MDR TB Urgent Research Priorities. Gerald Friedland MD Yale School of Medicine Nelson R Mandela School of Medicine
XDR and MDR TB Urgent Research Priorities Gerald Friedland MD Yale School of Medicine Nelson R Mandela School of Medicine The Year of MDR XDR TB CDC, WHO report on global XDR TB XDR TB defined Global distribution
More informationCosting of the Sierra Leone National Strategic Plan for TB
Costing of the Sierra Leone National Strategic Plan for TB 2016-2020 Introduction The Government of Sierra Leone established the National Leprosy Control Programme in 1973 with support from the German
More informationEpidemiology of anti-tuberculosis drug resistance in a chinese population: current situation and challenges ahead
RESEARCH ARTICLE Open Access Epidemiology of anti-tuberculosis drug resistance in a chinese population: current situation and challenges ahead Yan Shao 1,DandanYang 1,WeiguoXu 1, Wei Lu 1, Honghuan Song
More informationTB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)
TB IN EMERGENCIES Department of Epidemic and Pandemic Alert and Response (EPR) Health Security and Environment Cluster (HSE) (Acknowledgements WHO Stop TB Programme WHO/STB) 1 Why TB? >33% of the global
More informationIPT BOTSWANA EXPERIENCE
IPT BOTSWANA EXPERIENCE Oaitse I Motsamai RN, MW, B Ed, MPH Ministry of Health Botswana 11 th November 2008 Addis Ababa, Ethiopia OUTLINE Botswana context Rationale for IPT in Botswana Pilot Current Programme
More informationMIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex
MIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex Marie Claire Rowlinson, PhD D(ABMM) Florida Bureau of Public Health Laboratories
More information511,000 (57% new cases) ~50,000 ~30,000
Latest global TB estimates - 2007 (Updated Mar 2009) All forms of TB Greatest number of cases in Asia; greatest rates per capita in Africa Multidrug-resistant TB (MDR-TB) Estimated number of cases 9.27
More informationTB Program and Epidemic aka B2B
TB Program and Epidemic aka B2B Nulda Beyers On behalf of DTTC BOD Workshop 30 September2013 Trend in tuberculosis incidence, selected countries in Africa 1400 1200 Rate per 100,000 1000 800 600 400 200
More informationCalifornia s Experiences Using Tuberculosis Whole Genome Sequencing
California s Experiences Using Tuberculosis Whole Genome Sequencing Martin Cilnis MS, MPH Epidemiologist California Department of Public Health, TB Control Branch, Outbreak Prevention and Control Section
More informationTUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director.
30 August 2007 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-seventh session Brazzaville, Republic of Congo, 27 31 August Provisional agenda item 7.8 TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE
More information2010 global TB trends, goals How DOTS happens at country level - an exercise New strategies to address impediments Local challenges
Outline of what it will take Tuberculosis Elimination 25: Global and Local Challenges Anne Fanning, MD November 9, 211 21 global TB trends, goals How DOTS happens at country level - an exercise New strategies
More informationDemocratic People s Republic of Korea
National TB prevalence survey Democratic People s Republic of Korea Technical Brief TB National Prevalence Survey Democratic People s Republic of Korea Contents Acknowledgement...iv Acronyms...v Executive
More informationTUBERCULOSIS CONTROL SAARC REGION
TUBERCULOSIS CONTROL SAARC REGION UPDATE 2009 SAARC Tuberculosis & HIV/AIDS Centre (STAC) (Thimi, Bhaktapur), P. O. Box No. 9517, Kathmandu, Nepal. Tel: 6631048, 6632477, 6632601 Fax: 00977-1-6634379 E-mail:
More informationTOG The Way Forward
TOG 2016- The Way Forward Main Changes in Diagnostic algorithm Definition (Type, Classification, Outcome) Registration at the time of Diagnosis (PHI level Notification Register) Long term follow up (till
More informationMaha R Farhat, MD MSc Massachusetts General Hospital Harvard Medical School. I have no financial or other potential conflicts of interest to disclose
Maha R Farhat, MD MSc Massachusetts General Hospital Harvard Medical School I have no financial or other potential conflicts of interest to disclose Update on the epidemiology of TB drug resistance Success
More informationShah: Discordant Growth- Molecular Rifampin Resistance 2/27/16 RELAPSED FAILED
/7/6 Discordant Growth- Molecular Diagnos7c Challenges and Treatment Outcomes Neha Shah, MD MPH Centers for Disease Control and Preven7on California Department of Health Tuberculosis Control NAR February
More informationManagement of Drug-resistant Tuberculosis (DR-TB)
Management of Drug-resistant Tuberculosis (DR-TB) Nitipatana Chierakul Division of Respiratory Disease & Tuberculosis Department of Medicine Faculty of Medicine Siriraj Hospital October 14 th, 2008 Tropical
More informationThe Lancet Infectious Diseases
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study Susan E Dorman, Samuel G Schumacher, David Alland et al. 2017
More informationSARS Prevention and Control in China. Mr. Gao Qiang Executive Vice Minister of Health People s Republic of China 17 June 2003 KuaLa Lumpur
SARS Prevention and Control in China Mr. Gao Qiang Executive Vice Minister of Health People s Republic of China 17 June 2003 KuaLa Lumpur Epidemic Situation 25 Provinces Have Reported SARS Probable Cases
More informationCalifornia s Experiences Using Tuberculosis Whole Genome Sequencing
California s Experiences Using Tuberculosis Whole Genome Sequencing Martin Cilnis MS, MPH Epidemiologist California Department of Public Health, TB Control Branch, Outbreak Prevention and Control Section
More informationRapid Diagnosis and Detection of Drug Resistance in Tuberculosis
Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries
More informationXDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS. Enrico Girardi Unità di Epidemiologia Clinica INMI Spallanzani, Roma. Pag. 1
XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS Enrico Girardi Unità di Epidemiologia Clinica INMI Spallanzani, Roma Pag. 1 TB estimated incidence in EUR, 2004 Russian Fed. 12 th among the 22 TB high-burden
More informationOsaka City is the third largest city (population
Surveillance Report Strengthened tuberculosis control programme and trend of multidrug resistant tuberculosis rate in Osaka City, Japan Akira Shimouchi, a Akihiro Ohkado, a Kenji Matsumoto, b Jun Komukai,
More informationWhat can be done against XDR-TB?
What can be done against XDR-TB? Dr Matteo Zignol Stop TB Dep. World Health Organization Geneva 16 th Swiss Symposium on tuberculosis Münchenwiler, 22 March 2007 XDR-TB Extensive Drug Resistance XDR =
More informationTreatment of Tuberculosis, 2017
Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,
More informationPresented by Leigh Snyman April 2017
Presented by Leigh Snyman April 2017 Overview Definition of Palliative Care Case based discussion Take home messages What is Palliative Care? WHO Definition of Palliative Care: Palliative care is an approach
More informationTuberculosis Reference Laboratory, NIDCH, Mahakhali, Dhaka.
Bangladesh J Med Microbiol 2011; 05 (02): 06-10 Bangladesh Society of Medical Microbiologists Original Article A rapid Drug Susceptibility Test (DST) for detection of Multi-Drug Resistant (MDR) Mycobacterium
More informationDRUG RESISTANCE IN TUBERCULOSIS CONTROL. A GLOBAL AND INDIAN SITUATION
JOURNAL OF PREVENTIVE MEDICINE 2008; 16(3-4): 3-9 Inviting Editorial DRUG RESISTANCE IN TUBERCULOSIS CONTROL. A GLOBAL AND INDIAN SITUATION Harshad Thakur Centre for Health Policy, Planning and Management,
More informationContact Follow-Up and Treatment of LTBI in Households of Infectious Cases in Pakistan
Contact Follow-Up and Treatment of LTBI in Households of Infectious Cases in Pakistan 17 th Annual Conference, The Union-North American Region, Vancouver, Canada. 28 February 2013 Farhana Amanullah Director
More informationOverview of the WHO policy on TB Infection Control and practical aspects and implementation tools for effective IC measures in Health facilities
Overview of the WHO policy on TB Infection Control and practical aspects and implementation tools for effective IC measures in Health facilities Dr. M. Angélica Salomão Medical Officer DOTS Expansion &
More informationMultidrug-resistant tuberculosis in children
Multidrug-resistant tuberculosis in children James Seddon Clinical Lecturer Imperial College London UCL-TB and LSHTM TB Centre World TB Day 2015 24th March 2015 Outline Burden Recent studies Preventive
More informationTuberculosis in Greece: bacteriologically confirmed cases and anti-tuberculosis drug resistance,
Surveillance and outbreak reports Tuberculosis in Greece: bacteriologically confirmed cases and anti-tuberculosis drug resistance, 1995-2009 D Papaventsis (dpapaventsis@yahoo.gr) 1, S Nikolaou 1, S Karabela
More informationTuberculosis: The Big Picture And Challenge of Drug-resistance
5 th APHL National Conference on Laboratory Aspects of Tuberculosis August 11-13, 2008 San Diego, California Tuberculosis: The Big Picture And Challenge of Drug-resistance RADM Kenneth G. Castro, M.D.
More informationThe first National TB Prevalence Survey Rwanda 2012
The first National TB Prevalence Survey Rwanda 2012 Preliminary Results 29 th April 2013 Patrick Migambi Rwanda Biomedical Centre (RBC) Background Indicator (2011) Population size(census 2012) 10,537,222
More informationOutline. Tuberculosis (TB) Medical Evaluation for TB 5/5/2014. Chest Radiograph with Lower Lobe Cavity
Jean Beinemann RN, Terri Boxrucker RN, and LT Dee Dee Downie MPH Outline The disease The outbreak The response The conclusions May 18, 2014 Wisconsin Public Health Association Annual Meeting Tuberculosis
More informationTB BASICS: PRIORITIES AND CLASSIFICATIONS
TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE NOVEMBER 1-4, 2016 TB BASICS: PRIORITIES AND CLASSIFICATIONS LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1.
More information2. Treatment coverage: 3. Quality of care: 1. Access to diagnostic services:
The theme for World TB Day 2014 is Reach the missed 3 million. Every year 3 million people who fall ill with TB are missed by health systems and do not always get the TB services that they need and deserve.
More informationGlobal MDR-TB Update GIDC. Paul Nunn, MA, FRCP(UK) Director, Global Infectious Disease Consulting London, UK
Global MDR-TB Update Paul Nunn, MA, FRCP(UK) Director, Global Infectious Disease Consulting London, UK Acknowledgements Matteo Zignol Mario Raviglione All the WHO staff in drug resistance surveillance
More informationMultidrug-Resistant TB
Multidrug-Resistant TB Diagnosis Treatment Linking Diagnosis and Treatment Charles L. Daley, M.D. National Jewish Health University of Colorado Denver Disclosures Chair, Data Monitoring Committee for delamanid
More informationStrengthening and aligning diagnosis and treatment of drug-resistant TB in Russian Federation
LOGO Strengthening and aligning diagnosis and treatment of drug-resistant TB in Russian Federation Irina A.Vasilyeva Chief TB Specialist of the Russian Ministry of Health Central TB Research Institute,
More informationMulti-country surveillance project on fluoroquinolones and PZA resistance
Multi-country surveillance project on fluoroquinolones and PZA resistance Matteo Zignol CPTR Rapid DST 2014 Workshop September 22-23, 2014 Washington DC, US Objectives of the FQLs and PZA surveillance
More informationTB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012
TB Nurse Case Management San Antonio, Texas March 7-9, 2012 Diagnosis of TB: Laboratory Ken Jost Wednesday March 7, 2012 Ken Jost has the following disclosures to make: No conflict of interests No relevant
More informationArticles. Funding Bill & Melinda Gates Foundation. Copyright Li et al. Open Access article distributed under the terms of CC BY-NC-ND.
Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrugresistant tuberculosis in China: a before-and-after study Renzhong Li*, Yunzhou Ruan*, Qiang Sun*,
More informationMDR TB. Jaime C. Montoya MD, MSc
MDR TB Jaime C. Montoya MD, MSc Definitions of MDRTB and XDRTB Historical background of the problem Global and Philippine Data on MDRTB Risk Factors Diagnosis Treatment Research Gaps Guidelines for the
More informationThe Laboratories Role in Global Health
The Laboratories Role in Global Health Larry Westerman, Ph.D. International Laboratory Branch Division of Global HIV/AIDS Centers for Disease Control and Prevention Center for Global Health International
More information